Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review.
Aurora kinases (AKs) represent a novel group of serine/threonine kinases. They were originally described in 1995 by David Glover in the course of studies of mutant alleles characterized with unusual spindle pole configuration in Drosophila melanogaster. Thus far, three AKs A, B, and C have been discovered in human healthy and neoplastic cells. Each one locates in different subcellular locations and they are all nuclear proteins. AKs are playing an essential role in mitotic events such as monitoring of the mitotic checkpoint, creation of bipolar mitotic spindle and alignment of centrosomes on it, also regulating centrosome separation, bio-orientation of chromosomes and cytokinesis. Any inactivation of them can have catastrophic consequences on mitotic events of spindle formation, alignment of centrosomes and cytokinesis, resulting in apoptosis. Overexpression of AKs has been detected in diverse solid and hematological cancers and has been linked with a dismal prognosis. After discovery and identification of the first aurora kinase inhibitor (AKI) ZM447439 as a potential drug for targeted therapy in cancer treatment, approximately 30 AKIs have been introduced in cancer treatment.
Department of Surgical Oncology, Theageneio Anticancer Hospital, Thessaloniki, Greece.
Paschalis
P
Gavriilidis
Department of Transplantation Surgery, Hippokrateion University Hospital, Thessaloniki, Greece.
Alexandros
A
Giakoustidis
Department of Transplantation Surgery, Hippokrateion University Hospital, Thessaloniki, Greece.
Dimitrios
D
Giakoustidis
Aurora kinase inhibitors; Aurora kinases A, B and C; Serine/threonine kinases